Welcome to our dedicated page for Mirum Pharmaceuticals news (Ticker: MIRM), a resource for investors and traders seeking the latest updates and insights on Mirum Pharmaceuticals stock.
Mirum Pharmaceuticals, Inc. develops and commercializes medicines for rare diseases, with recurring updates centered on product sales, clinical readouts, regulatory interactions and employee equity grants. The company’s commercial portfolio includes LIVMARLI® (maralixibat) for Alagille syndrome and progressive familial intrahepatic cholestasis, CHOLBAM® (cholic acid) for bile-acid synthesis disorders, and CTEXLI® (chenodiol) for cerebrotendinous xanthomatosis.
News about MIRM also covers clinical-stage programs including volixibat, an IBAT inhibitor for primary sclerosing cholangitis and primary biliary cholangitis; brelovitug, a monoclonal antibody designed to bind hepatitis B surface antigen for chronic hepatitis delta virus; and MRM-3379, a PDE4D inhibitor for Fragile X syndrome. Company updates report financial results, pipeline licensing activity and inducement awards under Nasdaq Listing Rule 5635(c)(4).
Mirum Pharmaceuticals (Nasdaq:MIRM) granted equity inducement awards to 12 new employees under its 2020 Inducement Plan on May 11, 2026. Awards include non-qualified stock options for 22,950 shares at an exercise price of $106.17 and 31,300 RSUs, issued under Nasdaq Listing Rule 5635(c)(4).
Options vest over four years; RSUs vest over three years, subject to continued service.
Mirum Pharmaceuticals (Nasdaq:MIRM) priced $600.0 million of 0.00% convertible senior notes due 2032 in a Rule 144A private placement, with a $90.0 million option for additional notes.
Net proceeds are estimated at $583.8–$671.6 million, partly used to refinance 4.00% 2029 notes and for general corporate purposes.
Mirum Pharmaceuticals (Nasdaq:MIRM) plans a private offering of $600 million convertible senior notes due 2032 to qualified institutional buyers under Rule 144A, with an option for an additional $90 million. Proceeds will partly fund cash consideration in exchanges of its 4.00% convertible notes due 2029 and support general corporate purposes, including possible acquisitions.
Mirum Pharmaceuticals (Nasdaq:MIRM) will participate in two upcoming investor conferences in May 2026. Management will join fireside chats at the H.C. Wainwright 4th Annual BioConnect Investor Conference and the 2026 RBC Capital Markets Global Healthcare Conference.
Live and archived webcasts will be available in the Investors section of Mirum’s website.
Mirum Pharmaceuticals (Nasdaq: MIRM) reported Q1 2026 net product sales of $159.9 million and raised 2026 net product sales guidance to $660–$680 million. LIVMARLI sales were $113.8 million (+55% YoY); Bile Acid Medicines sales were $46.1 million (+20% YoY). Clinical updates: volixibat VISTAS and brelovitug AZURE-1 Phase 2b met primary endpoints. Mirum licensed zilurgisertib for FOP; the FDA accepted the NDA and granted Priority Review with a PDUFA date of Sept 26, 2026. Q1 operating expenses included a $726.3 million non-recurring IPR&D charge; cash, cash equivalents, and investments were $420.6 million as of March 31, 2026.
Mirum Pharmaceuticals (Nasdaq: MIRM) reported that the VISTAS Phase 2b study of volixibat in primary sclerosing cholangitis met its primary endpoint. In the primary cohort (n=111) volixibat showed an LS mean itch change of -2.72 versus -1.08 for placebo; placebo-adjusted difference -1.64 (p<0.0001). Secondary signals included ≥2-point responder rate 55.6% vs 26.3% (difference 29.3%, p=0.0019) and sBA reduction. Safety showed more GI events, liver lab elevations, and higher discontinuations with volixibat. A pre-NDA meeting with FDA is scheduled for summer 2026 and an NDA filing is planned in H2 2026; full results will be presented May 30 at EASL.
Mirum Pharmaceuticals (Nasdaq: MIRM) will host an investor call on May 4, 2026 at 8:30 a.m. ET / 5:30 a.m. PT to share topline results from the VISTAS study of volixibat in patients with primary sclerosing cholangitis (PSC).
Access is by US toll-free and international phone numbers or via webcast on the company Investors website; an archived replay will be available.
Mirum Pharmaceuticals (Nasdaq: MIRM) will report first quarter 2026 financial results and host a conference call on May 6, 2026 at 4:30 p.m. ET / 1:30 p.m. PT.
Dial-in numbers and an international line are provided; a live webcast and archived replay will be available via the Investors section of Mirum's website.
Mirum Pharmaceuticals (Nasdaq: MIRM) reported that the Phase 2b portion of AZURE-1 met its primary composite endpoint at Week 24 for brelovitug in chronic hepatitis delta virus (HDV).
At Week 24, virologic response occurred in 100% (300 mg QW) and 75% (900 mg Q4W) versus 0% delayed; composite endpoint achieved in 45% and 35% versus 0%. Safety was described as favorable. Full Phase 2b results will be presented at EASL May 27-30, 2026; Phase 3 toplines expected H2 2026.
Mirum Pharmaceuticals (Nasdaq: MIRM) announced inducement grants on April 10, 2026: non-qualified stock options to purchase 13,700 shares and 18,200 restricted stock units issued to 12 new employees under the 2020 Inducement Plan.
Each option has an exercise price of $95.20 (closing price on April 10, 2026). Options vest over four years (25% after one year, then monthly over 36 months). RSUs vest over three years (33% each anniversary). Awards are subject to plan and award agreement terms.